📊 EUDAW Key Takeaways
Is EUDA Health Holdings Ltd (EUDAW) a Good Investment?
EUDA Health faces severe financial distress with negative stockholders' equity of -$6.0M, indicating liabilities exceed assets. The company is unprofitable with a -6.0% net margin and negative free cash flow of -$488K, while generating minimal gross profit (1.0% margin) on $40.1M in revenue, suggesting fundamental operational inefficiencies.
EUDA Health Holdings shows very weak underlying fundamentals: gross margin is only 1.0%, operating and net margins are negative, and the company is not generating enough profitability to support its revenue base. Financial health is also strained, with negative stockholders' equity, sub-1.0 liquidity ratios, low cash reserves, and negative free cash flow, which together point to elevated balance-sheet and execution risk.
Why Buy EUDA Health Holdings Ltd Stock? EUDAW Key Strengths
- Positive revenue base of $40.1M provides foundation for operations
- No significant long-term debt burden disclosed
- Cash position of $837.3K provides short-term liquidity runway
- Revenue scale is meaningful at $40.10M, indicating an established operating base
- Operating cash burn is relatively modest versus revenue, suggesting losses are not yet deeply cash-destructive
- Capital expenditure requirements appear low, which can reduce near-term reinvestment pressure
EUDAW Stock Risks: EUDA Health Holdings Ltd Investment Risks
- Negative stockholders' equity (-$6.0M) indicates technical insolvency and high bankruptcy risk
- Severely negative cash flow generation (-$469.9K operating cash flow) is unsustainable without external funding
- Extremely low gross margin (1.0%) suggests pricing power issues, cost structure problems, or inability to scale profitably
- Current ratio of 0.79x indicates insufficient current assets to cover near-term obligations
- Negative operating margin (-4.9%) demonstrates core business is unprofitable before financing costs
- Extremely thin 1.0% gross margin leaves almost no cushion for overhead, pricing pressure, or cost inflation
- Negative stockholders' equity and liabilities exceeding assets indicate a structurally weak balance sheet
- Current and quick ratios of 0.79x combined with only $837K of cash create liquidity and funding risk
Key Metrics to Watch
- Gross margin expansion and path to profitability
- Operating cash flow trend and cash burn rate
- Ability to reduce debt/liabilities and restore positive equity
- Gross margin improvement and sustained positive operating margin
- Liquidity position, especially cash balance and current ratio
EUDA Health Holdings Ltd (EUDAW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EUDAW Profit Margin, ROE & Profitability Analysis
EUDAW vs Services Sector: How EUDA Health Holdings Ltd Compares
How EUDA Health Holdings Ltd compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EUDA Health Holdings Ltd Stock Overvalued? EUDAW Valuation Analysis 2026
Based on fundamental analysis, EUDA Health Holdings Ltd has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EUDA Health Holdings Ltd Balance Sheet: EUDAW Debt, Cash & Liquidity
EUDAW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: EUDA Health Holdings Ltd's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.09 reflects profitable operations.
EUDAW Revenue Growth, EPS Growth & YoY Performance
EUDAW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | $1.7M | $218.8K | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EUDA Health Holdings Ltd Dividends, Buybacks & Capital Allocation
EUDAW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for EUDA Health Holdings Ltd (CIK: 0001847846)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EUDAW
What is the AI rating for EUDAW?
EUDA Health Holdings Ltd (EUDAW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EUDAW's key strengths?
Claude: Positive revenue base of $40.1M provides foundation for operations. No significant long-term debt burden disclosed. ChatGPT: Revenue scale is meaningful at $40.10M, indicating an established operating base. Operating cash burn is relatively modest versus revenue, suggesting losses are not yet deeply cash-destructive.
What are the risks of investing in EUDAW?
Claude: Negative stockholders' equity (-$6.0M) indicates technical insolvency and high bankruptcy risk. Severely negative cash flow generation (-$469.9K operating cash flow) is unsustainable without external funding. ChatGPT: Extremely thin 1.0% gross margin leaves almost no cushion for overhead, pricing pressure, or cost inflation. Negative stockholders' equity and liabilities exceeding assets indicate a structurally weak balance sheet.
What is EUDAW's revenue and growth?
EUDA Health Holdings Ltd reported revenue of $40.1M.
Does EUDAW pay dividends?
EUDA Health Holdings Ltd does not currently pay dividends.
Where can I find EUDAW SEC filings?
Official SEC filings for EUDA Health Holdings Ltd (CIK: 0001847846) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EUDAW's EPS?
EUDA Health Holdings Ltd has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EUDAW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, EUDA Health Holdings Ltd has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EUDAW stock overvalued or undervalued?
Valuation metrics for EUDAW: ROE of N/A (sector avg: 16%), net margin of -6.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy EUDAW stock in 2026?
Our dual AI analysis gives EUDA Health Holdings Ltd a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EUDAW's free cash flow?
EUDA Health Holdings Ltd's operating cash flow is $-469.9K, with capital expenditures of $18.1K. FCF margin is -1.2%.
How does EUDAW compare to other Services stocks?
Vs Services sector averages: Net margin -6.0% (avg: 10%), ROE N/A (avg: 16%), current ratio 0.79 (avg: 1.5).